The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Open accessAbstract
BACKGROUND: Multidrug-resistant (MDR) tuberculosis (TB) has emerged as a global epidemic, with ~425,000 new cases estimated to occur annually. The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence. METHODS: We reviewed published studies and available surveillance data evaluating links between HIV infection and MDR-TB to quantify convergence of these 2 epidemics, evaluate the consequences, and determine essential steps to address these epidemics. RESULTS: Institutional outbreaks of MDR-TB have primarily affected HIV-infected persons. Delayed diagnosis, inadequate initial treatment, and prolonged infectiousness led to extraordinary attack rates and case-fatality rates among HIV-infected persons. Whether this sequence occurs in communities is less clear. MDR-TB appears not to cause infection or disease more readily than drug-susceptible TB in HIV-infected persons. HIV infection may lead to malabsorption of anti-TB drugs and acquired rifamycin resistance. HIV-infected patients with MDR-TB have unacceptably high mortality; both antiretroviral and antimycobacterial treatment are necessary. Simultaneous treatment requires 6-10 different drugs. In HIV-prevalent countries, TB programs struggle with increased caseloads, which increase the risk of acquired MDR-TB. Surveillance data suggest that HIV infection and MDR-TB may converge in several countries. CONCLUSIONS: Institutional outbreaks, overwhelmed public health programs, and complex clinical management issues may contribute to the convergence of the MDR-TB and HIV infection epidemics. To forestall disastrous consequences, infection control, rapid case detection, effective treatment, and expanded program capacity are needed urgently.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732
Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., & Friedland, G. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200901 · Cited by 1,574
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Self-citationEdlin, B. R., Tokars, J. I., Grieco, M. H., Crawford, J. T., Williams, J., Sordillo, E. M., Ong, K. R., Kilburn, J. O., Dooley, S. W., Castro, K. G., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206043262302 · Cited by 861
Self-citationGlobal Surveillance for Antituberculosis-Drug Resistance, 1994–1997
Pablos-Méndez, A., Raviglione, M. C., Laszlo, A., Binkin, N., Rieder, H. L., Bustreo, F., Cohn, D. L., Lambregts-van Weezenbeek, C. S. B., Kim, S. J., Chaulet, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382301 · Cited by 815
Accelerated course of human immunodeficiency virus infection after tuberculosis.
Whalen, C., Horsburgh, C. R., Hom, D., Lahart, C., Simberkoff, M., & Ellner, J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.1.7812542 · Cited by 535
Global Incidence of Multidrug‐Resistant Tuberculosis
Zignol, M., Hosseini, M. S., Wright, A., Weezenbeek, C. L., Nunn, P., Watt, C. J., Williams, B. G., & Dye, C. (2006) · The Journal of Infectious Diseases · doi:10.1086/505877 · Cited by 524
Small, P. M., Shafer, R. W., Hopewell, P. C., Singh, S. P., Murphy, M. J., Desmond, E., Sierra, M. F., & Schoolnik, G. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304223281601 · Cited by 512
Espinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507
Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru
Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcántara, F., Sánchez, E., Sarria, M., Becerra, M., Fawzi, M. C. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022928 · Cited by 489
Cited by
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Self-citationPoint-of-Care Diagnostics for Global Health
Yager, P., Domingo, G. J., & Gerdes, J. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.10.061807.160524 · Cited by 1,076
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
“MDR-TB is also a growing problem in South Africa, where high rates of HIV (human immunodeficiency virus) have exacerbated both the spread and deadliness of MDR-TB, raising the specter of a “perfect storm” of MDR-TB/HIV coinfection (Wells et al. 2007).”
BackgroundLawn, S. D., & Zumla, A. I. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62173-3 · Cited by 751
HIV Infection–Associated Tuberculosis: The Epidemiology and the Response
Getahun, H., Gunneberg, C., Granich, R., & Nunn, P. (2010) · Clinical Infectious Diseases · doi:10.1086/651492 · Cited by 598
Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017601 · Cited by 583
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialOrenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Newton, S. M., Brent, A. J., Anderson, S., Whittaker, E., & Kampmann, B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70182-8 · Cited by 480
Getahun, H., Kittikraisak, W., Heilig, C. M., Corbett, E. L., Ayles, H., Cain, K. P., Grant, A. D., Churchyard, G. J., Kimerling, M., Shah, S., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000391 · Cited by 404
Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60331-7 · Cited by 385
Gandhi, N. R., Shah, N. S., Andrews, J. R., Vella, V., Moll, A. P., Scott, M., Weissman, D., Marra, C., Lalloo, U. G., & Friedland, G. H. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200907-0989oc · Cited by 313
Vassall, A., van Kampen, S., Sohn, H., Michael, J. S., John, K. R., den Boon, S., Davis, J. L., Whitelaw, A., Nicol, M. P., Gler, M. T., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001120 · Cited by 313
Lange, C., Abubakar, I., Alffenaar, J.-W. C., Bothamley, G., Caminero, J. A., Carvalho, A. C. C., Chang, K.-C., Codecasa, L., Correia, A., Crudu, V., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00188313 · Cited by 310
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010
Zignol, M., van Gemert, W., Falzon, D., Sismanidis, C., Glaziou, P., Floyd, K., & Raviglione, M. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.092585 · Cited by 295
Transmission of Extensively Drug-Resistant Tuberculosis in South Africa
Shah, N. S., Auld, S. C., Brust, J. C. M., Mathema, B., Ismail, N., Moodley, P., Mlisana, K., Allana, S., Campbell, A., Mthiyane, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1604544 · Cited by 281
Lawn, S. D., Brooks, S. V., Kranzer, K., Nicol, M. P., Whitelaw, A., Vogt, M., Bekker, L.-G., & Wood, R. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001067 · Cited by 278
A Critical Role for CD8 T Cells in a Nonhuman Primate Model of Tuberculosis
Chen, C. Y., Huang, D., Wang, R. C., Shen, L., Zeng, G., Yao, S., Shen, Y., Halliday, L., Fortman, J., McAllister, M., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000392 · Cited by 278
Pathogenesis, Immunology, and Diagnosis of Latent Mycobacterium tuberculosis Infection
Ahmad, S. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/814943 · Cited by 271
Drug-resistant tuberculosis: time for visionary political leadership
Abubakar, I., Zignol, M., Falzon, D., Raviglione, M., Ditiu, L., Masham, S., Adetifa, I., Ford, N., Cox, H., Lawn, S. D., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70030-6 · Cited by 269
Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action
Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., & Nacy, C. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.56 · Cited by 269
Global Epidemiology of Tuberculosis
Glaziou, P., Sismanidis, C., Floyd, K., & Raviglione, M. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017798 · Cited by 252
Metadata
- Authors
- Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07
- Volume
- 196
- Issue
- s1
- Pages
- S86-S107
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2124019099
- Cited by
- 483
- References
- 96
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.